Abstract | BACKGROUND AND STUDY AIM: PATIENTS AND METHODS: 129 patients (surgical trial 70, medical trial 59) with Barrett's esophagus (nondysplastic or low grade dysplasia) were randomly allocated to either ablation using APC or to continuing endoscopy surveillance. Outcomes were determined at three time points: short-term (12 months), mid-term (42-75 months) and long-term (> 84 months). RESULTS: In the APC groups, initial ablation of > 95 % of the Barrett's esophagus was achieved in 61 of 63 patients; the > 95 % ablation persisted in 47 of 56 patients at short-term follow-up, in 33 of 49 at mid-term and in 21 of 32 at long-term follow-up. In the surveillance groups, the length of Barrett's esophagus reduced from a mean of 4.2 cm to 2.7 cm at long-term follow-up. High grade dysplasia (HGD) developed in 1 patient in the APC groups and in 3 in the surveillance groups. Low grade dysplasia developed in 1 APC patient and in 6 surveillance patients. CONCLUSIONS: APC ablation reduced the extent of Barrett's esophagus, and this reduction was maintained in some patients at longer-term follow-up. However, progression to HGD can still occur despite APC ablation, suggesting endoscopic surveillance is still required. CLINICAL TRIAL REGISTRATION: ACTRN012607000293460 and ACTRN12607000292471 (Australian Clinical Trials Registry).
|
Authors | Corina Sie, Tim Bright, Mark Schoeman, Philip Game, William Tam, Peter Devitt, David Watson |
Journal | Endoscopy
(Endoscopy)
Vol. 45
Issue 11
Pg. 859-65
(Nov 2013)
ISSN: 1438-8812 [Electronic] Germany |
PMID | 24019134
(Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | © Georg Thieme Verlag KG Stuttgart · New York. |
Topics |
- Adult
- Aged
- Aged, 80 and over
- Argon Plasma Coagulation
- Barrett Esophagus
(etiology, therapy)
- Esophagoscopy
- Follow-Up Studies
- Gastroesophageal Reflux
(complications, therapy)
- Humans
- Middle Aged
- Single-Blind Method
- Treatment Outcome
- Watchful Waiting
|